Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

93 94 Next >

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides ↗

April 23, 2025

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.

Via Benzinga

Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect

April 23, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.

Via StockStory

Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip ↗

April 23, 2025

A post-hoc analysis showed more pronounced effects among patients on risperidone compared to those on other antipsychotics, the company said.

Via Stocktwits

Topics Intellectual Property

Stay updated with the S&P500 stocks that are on the move in today's after-hours session. ↗

April 22, 2025

After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.

Via Chartmill

Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock ↗

April 22, 2025

Via Benzinga

Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test ↗

April 22, 2025

The company spent $14 billion to acquire the developer of this drug, Cobenfy.

Via Investor's Business Daily

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

April 22, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗

April 21, 2025

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use

Via Benzinga

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

April 21, 2025

Via Benzinga

U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

April 17, 2025

From Bristol Myers Squibb

Via Business Wire

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

April 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? ↗

April 15, 2025

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Via Benzinga

Which S&P500 stocks are moving on Tuesday? ↗

April 15, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

Via Chartmill

What's going on in today's session: S&P500 gap up and gap down stocks ↗

April 15, 2025

Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It ↗

April 14, 2025

The companies are facing off with their heart drugs in a growing disease area.

Via Investor's Business Daily

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

April 14, 2025

From Bristol Myers Squibb

Via Business Wire

These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗

April 13, 2025

Large-cap stocks, such as PDD, PBR, KMX, APTV, STLA, CRWV, BMY, Z, BABA, and YUMC, saw significant declines due to trade tensions and missed earnings.

Via Benzinga

Topics World Trade

Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock. ↗

April 12, 2025

Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.

Via Chartmill

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

April 11, 2025

From Bristol Myers Squibb

Via Business Wire

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗

April 11, 2025

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Via Benzinga

3 Value Stocks in the Doghouse

April 11, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Topics Government Stocks World Trade

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗

April 10, 2025

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Via Benzinga

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

April 10, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

What's going on in today's session: S&P500 movers ↗

April 09, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

April 09, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday? ↗

April 09, 2025

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

Via Benzinga

Topics World Trade

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients ↗

April 09, 2025

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results.

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.